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 Abstract 
Background : Port-related bloodstream infection (PRBSI) is a common complication associated 
with long-term use of ports systems. Systemic antimicrobial therapy (ST) and removal of the 
device is the standard management of PRBSI. However, a conservative management combining ST 
with antibiotic lock therapy (ALT) without port removal has been suggested as an alternative 
management option for infections due to gram-positive skin colonizers with low virulence. 
Objectives :  i) to assess the frequency of management of PRBSI in onco-hematological patients by 
combining the ALT with ST, without catheter removal and ii) to analyze the efficacy of such an 
approach. 
Methods : Retrospective observational study over a 6-year period between 2005 and 2010, 
including patients who where diagnosed with PRBSI and who were treated with ST and ALT. PRBSI 
diagnosis consisted in clinical signs of bacteremia with blood cultures positive for gram-positive 
skin colonizers. The primary endpoint was failure to cure the PRBSI. 
Results : 61 port infections were analysed, of which 23 PRBSI met the inclusion criteria. All the 
patients were suffering from haematological conditions and 75% were neutropenic at the time of 
PRBSI diagnosis. S. epidermidis was responsible for 91% of PRBSI (21/23). The median duration of 
ST was 14 days (range 7-35) and the median duration of ALT was 15 days (range 8-41). Failure to 
cure the PRBSI requiring port removal was observed in 4 patients, but was not associated with 
severe infectious complications. Kaplan-Meier analysis showed a success rate in port salvage at 
day 180 (6 months) of 78% (95%CI 59-97%). 
Conclusion : The success rate observed in the present study suggests that combining ST and ALT is 
an effective option to conservatively treat PRBSI caused by pathogens of low virulence such as S. 
epidermidis. 
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Background 
Long-term implantable central venous catheters have been used for over 40 years (1). Totally 
implantable venous access devices or “ports” are first described in the article of Belin et al in 1972 
(2,3). Numbers on totally implantable ports inserted each year are not available in the literature. 
Mermel et al reported in 2001 that more than 5 millions central venous catheters are inserted 
each year in the United States (4), including port systems. One can assume that their number is 
growing as daily practice suggests, especially in hematological or oncological patients. There was 
an estimated total number of 2143 ports implanted at CHUV between 2005 and 2010 according to 
the “CHOP1” code 86.07 encoding for this procedures regardless of the indication for port 
placement (source: Service of archives and medical coding, CHUV). Because of multiple 
manipulations during the prolonged use of ports, port-related bloodstream infection (PRBSI) is a 
frequent complication. A systematic review of 14 prospective studies reported a PRBSI rate of 3.6 
episodes/100 ports and of 0.1 episodes/1000 port-days (5). The first step of the pathogenesis of 
PRBSI is characterized by the colonisation of the catheter hub with biofilm-producing 
microorganism (6). The main microorganisms involved in PRBSIs are Gram positive cocci, 
responsible for 65.5% of episodes, including Coagulase-negative staphylococci (mainly S. 
epidermidis), Staphylococcus aureus, and Enterococcus spp (7–9). Gram negative bacilli account 
for 21% of cases: Enterobacteriacae spp., Acinetobacter spp., and Pseudomonas aeruginosa (7–9). 
Gram positive bacilli, e.g. Corynebacterium spp, (7–9) and yeasts (Candida spp.) account for 10% 
and 3.5% of cases, respectively (7–9). The standard management of PRBSI includes systemic 
antimicrobial therapy and catheter removal (7). However, in PRBSI due to coagulase-negative 
streptococci, some Gram-negative bacilli (E. coli, Enterobacter spp.) and other Gram-positive 
microorganisms (Corynebacterium spp., Enterococcus spp. S. mitis), the combination of systemic 
antimicrobial therapy (ST) and intraluminal therapy, so called “antibiotic-lock therapy” (ALT) 
without catheter removal, has been suggested as a management option (7–9). The first study 
reporting antibiotic lock therapy for treating catheter-related bacteraemia by Messing B et al in 
1988 (10) suggested that catheter-related sepsis can be managed without catheter removal with 
high success rates by using a “lock” consisting in filling the catheter lumen with 2ml of a highly 
concentrated antibiotic solution. The rationale of this approach was that antibiotic concentrations 
100-1000 times greater than the usual systemic concentrations were able to eradicate bacteria in 
catheter biofilms and that this was made possible by using the lock technique, without systemic 
toxicity of high dose antimicrobial therapy (4). The success rate, i.e. catheter salvage, reported in 
this first study on catheter locks was 91%. Since then, clinical studies have reported catheter-
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salvage rates ranging between 75 and more than 80% (4-6). Nevertheless, most studies have 
analyzed long-term catheters without distinction between tunneled devices (Broviac, Hickmann) 
and ports. Four studies treating PRBSI specifically were found: Megged et al (11), Sanchez-Munoz 
et al (12) and Del Pozo et al (13,14) reported success rates from 18 to 89% for the management of 
port-related bacteremia with systemic antimicrobial treatment associated with antibiotic lock 
therapy. 3 other studies focused on treatment of catheter-related bacteremia, regardless on the 
type of device (15–17): a specific subgroup analysis of ports data showed estimated success rates 
varying from 77% to 94%. Based on the above data, clinical guidelines recommend this type of 
treatment for long-term catheter-related bloodstream infections. Data on use of this approach for 
PRBSI management at Centre Hospitalier Universitaire Vaudois (CHUV) are lacking and a 
systematic, standardized procedure is not available. 
The aim of this study was i) to assess the frequency of management of PRBSI in onco-
hematological patients by combining the antibiotic-lock technique with systemic antimicrobial 
therapy, without catheter removal and ii) to analyze the efficacy of such an approach.  
Patients, methods and definitions 
Study design. This observational retrospective study included patients with PRBSI hospitalized in 
the Isolation ward of the Infectious Disease Service of the Department of Medicine at CHUV 
between January 1st, 2005 and December 31st, 2010. All discharge letters over the study period 
have been screened in order to identify patients with PRBSI. Those who fulfilled the below 
inclusion criteria were included. The database of the Laboratory of microbiology (Molis) as well as 
charts for patients who were followed on an outpatient basis by the Hematology service or the 
Coordinated centre of oncology (CCO) were used as back-up source for additional information. 
Demographic, clinical, microbiological, treatment and follow-up data were retrospectively 
collected using standardized report forms and entered into a database (Microsoft Excel 2007).  
Institutional Ethics Committee approval for the use of medical information for research purposes 
was obtained. 
Patients. To be eligible for the study, the patients had to fulfill the following criteria: 1) age more 
than 18 years and hematological malignancy or solid tumor; 2) presence of a totally implantable 
device of type Port-a-Cath®; 3) PRBSI treated conservatively with systemic antibiotic therapy (ST) 
and ALT; 4) no planned removal of the port for reasons other than PRBSI within the following 30 
days. 
Exclusion criteria were those that required immediate port removal for the PRBSI: pocket or 
subcutaneous infection, complicated catheter-related infection (septic thrombosis, endocarditis, 
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osteomyelitis, metastatic seeding), severe sepsis or septic shock, infections with Candida spp or S. 
aureus or Gram-negatives. However, because additional data on successful management of Gram-
negative PRBSIs with ALT were found after submission of the protocol, it was decided to also 
include a posteriori two cases of Gram-negative bacteremia into the study. 
Study definitions. PRBSI was defined as clinical signs of bacteraemia (fever > 38°C, chills, 
hypotension) without another clinically obvious source of infection and positive blood cultures for 
CoNS or other Gram-positive skin colonizers drawn from the port plus/minus peripheral 
venipuncture. Qualitative blood cultures were drawn simultaneously from the port and from 
peripheral venipuncture: PRBSI was diagnosed as soon as one of these cultures were positive 
concomitantly to the clinical features listed above. Because differential time-to-positivity was not 
systematically used, this could not be used as a criterion for PRBSI in the present study. 
Infection type: community-acquired infection included infections occurring within 72 hours after 
hospitalization and no former hospital stay during the preceding 3 weeks. Hospital-acquired 
infection was considered when community-acquired infection criteria were not fulfilled. 
Treatment. Only patients who received both ST and ALT were considered. ST was divided into 
empirical and appropriate treatment as follows: i) empirical ST included any of the antimicrobial 
drugs given before the diagnosis of PRBSI, i.e. reporting of positive blood culture results from the 
microbiology lab to the physician in charge, regardless of the in vitro antibacterial susceptibility 
testing and ii) appropriate treatment was adapted to the in vitro antibacterial susceptibility 
testing. 
ALT was performed by using vancomycin or ciprofloxacin and ports were locked after the end of 
the ST. Vancomycin locks consisted in 2ml of 5mg/ml vancomycin solution mixed with heparin 
(Liquemine®) 100 IU/ml. Ciprofloxacin locks contained 2ml of 2mg/ml ciprofloxacin solution mixed 
with heparin 100 IU/ml. Because there is no systematic protocol on the length of the ALT, all lock 
durations were included into the study. Lock solutions were conserved in a fridge at 4°C for a 
maximum of 14 days. 
Outcome. Success was considered when the following criteria were fullfilled: 1) cure of the acute 
episode of PRBSI, 2) the catheter being still in place 6 months after PRBSI diagnosis (if the port had 
to be removed between 3 and 6 months after the end of the treatment for another reason than 
infection (i.e. end of chemotherapy, thrombosis, port extravasation, port obstruction/dysfunction 
or another reason) and port culture was sterile, the management was considered as a success), 3) 
no relapse of PRBSI with the same microorganism, based on the bacterial species identification 
and antibacterial susceptibility testing profile, 
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Failure was subdivided into three different types: 1) immediate failure, defined as lack of response 
of the acute episode of PRBSI requiring removal of the port within 7 days after the start of an 
appropriate antibacterial treatment, e.g. persistence of fever or persistent bacteremia or any 
other severe infectious complication (pocket or subcutaneous infection, septic thrombosis, 
endocarditis, osteomyelitis, metastatic seeding; severe sepsis or septic shock), 2) early failure, 
defined as a relapse of bacteraemia with the same microorganism (see above) within 7 to 30 days 
after start of appropriate antibacterial treatment, 3) Late failure, defined as relapse of PRBSI with 
the same microorganism (see above) between 30 days and 6 months. For patients who died 
within the evaluation period, additional data were collected in order to assess whether there were 
any criteria for treatment failure. 
Statistical analysis. Statistical analyses were performed using Microsoft office Excel 2007 and 
XLStat 2011 for Excel. 
Results 
Figure 1 summarizes the characteristics of 61 patients with PRBSI identified according to the 
systematic screening of the discharge letters. Data on the 66 microorganisms identified in these 
61 episodes of PRBSI are shown in table 1. S. epidermidis was the most common microorganism 
regardless of the type of PRBSI-management (ST/ALT, ST/port removal, other) and no PRBSI due 
to S. aureus (7% of all PRBSIs) received ALT. 5 polymicrobial infections were identified: 2 in the ST 
plus ALT group (S. epidermidis/S. mitis and S. epidermidis/E. coli), 2 in the ST plus port removal 
group (E. coli/S. aureus and E. coli/K. pneumoniae) and one due to yeasts (C. albicans/C. 
parapsilosis) was treated with systemic antifungal therapy and port removal.  
Of the 61 episodes of PRBSI identified during the study period, 26 (43%) were treated with 
systemic ST and ALT. 23 of these PRBSIs met the inclusion criteria, 2 episodes could not be 
analysed because of insufficient data and 1 episode was excluded from the study because it 
eventually did not receive any ALT. 
Clinical characteristics. Demographic, clinical, microbiological and treatment data of the 22 
patients with the 23 PRBSIs included into the study are shown in table 2. The male:female ratio 
was 2:1 and all patients were suffering from an haematological malignancy. 1 female patient had 
concomitant acute myeloid leukaemia and breast cancer. 21/23 (87%) patients were undergoing 
chemotherapy, 10 of which could not be classified into subgroups because of the heterogeneity of 
the treatments. Neutropenia (<0.5 G/l) was present in 17/23 (74%) of the patients at the time of 
PRBSI diagnosis. Port location was subclavian right (9/23, 39%) or left( 10/23, 43%), 1 patient had 
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a left femoral vein location and in 3/23 (13%) location information was not available. The most 
common clinical manifestation of PRBSI was fever (91%, 2 patients had no fever, but positive port 
blood cultures) and none of the patients who received ALT had any purulent discharge. In 20 
PRBSI episodes blood cultures were drawn simultaneously from both the port and peripheral 
venipuncture, while in 3 episodes blood cultures were only drawn from the port. 88/111 (79%) 
port blood cultures bottles were positive in 23/23 (100%) PRBSI episodes, while 28/83 (34%) 
peripheral blood cultures bottles were positive in 8/23 (34%) PRBSI episodes. Among positive port 
blood cultures, the following distribution of the number of positive bottles was observed: 4/4 
positive bottles in 52% (12/23) PRBSI episodes, 3/4 positive bottles in 22% (5/23), 2/4 positive 
bottles in 4% (1/23), and other proportions of positive bottles in 22% (5/23) (5/8 in 1, 4/8 in 1, 3/3 
in 1, 2/2 in 1, and 1/10 in 1). Among concomitant positive peripheral blood cultures, the following 
distribution of the number of positive bottles was observed: 4/4 in 62% (5/8), 3/4 in 25% (2/8), 
2/4 in 25% (1/8). When peripheral blood cultures bottles were 4/4 positive (5/8 episodes), port 
blood cultures were positive with 4/4 bottles in 3 episodes, 3/4 bottles in 1 and 5/8 bottles in 1. 
When peripheral blood cultures bottles were 3/4 positive (2/8 episodes), port blood cultures were 
positive with 2/2 bottles in 1 episode and 4/4 in 1.For the 1 episode with 2/4 positive peripheral 
blood culture bottles, 4/4 positive port blood culture bottles were observed. Two episodes might 
have been misdiagnosed and could consist of contamination rather than real PRBSI episodes: the 
first one had 1/10 positive port blood culture without any positive peripheral blood culture and 
the second one only had 2/4 positive port blood cultures without any positive peripheral blood 
culture. Microbiological data of the PRBSIs included into the study are shown in table 2. S. 
epidermidis was identified in 21/23 (91%) PRBSI. Gram-negatives were documented in 2 PRBSI : i) 
a co-infection with S. epidermidis and E. coli, probably reflecting a translocation due to GI-tract 
mucositis rather than a PRBSI, which was however managed as a PRBSI with an ALT combining 
vancomycin and ciprofloxacin, ii) an E. cloacae PRBSI, which occurred as a late complication of a 
GI-tract mucositis-associated bacteremia and was managed with a ciprofloxacin ALT. Despite 
being due to gram-negatives, as these PRBSI were both treated with ST and ALT, they were post-
hoc included into the study.  4/24 PRBSIs were community-acquired infections. Detailed individual 
characteristics on microbiology, treatment and outcome of the 23 episodes of PRBSI included into 
the study are presented in table 3. Note that PRBSI 8 and 9 occurred in the same patient at an 
interval of more than 12 months and were analysed separately, as the causative pathogen 
presented a different antibacterial susceptibility testing profile. 
Systemic therapy. Three patients did not receive any empirical therapy and among the remaining 
20 who did, 4 (20%) empirical therapies were not appropriate. The median duration of 
appropriate ST was 14 days (range 7 – 14 days). 20/23 PRBSIs (87%) received vancomycin as a 
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component of the ST. Median duration of vancomycin therapy was 7 days (range 1 – 19 days). 
Thirty-seven vancomycin through blood concentrations (VTBC) measurements were performed in 
16 patients. The overall median VTBC was 14.35 mg/l (range 4.30 – 36.40 mg/l) (n=16). Median 
VTBC higher than 10mg/l was reached in 12/16 patients (75%) and median VTBC higher than 
15mg/l in 7/16 patients (44%). Median time from PRBSI diagnosis to achievement of VTBC higher 
than 10mg/l was 2 days (range -13 – 10 days) (n=14). Median time to VTBC higher than 15 mg/l 
was 3 days (range -13 – 14 days) (n=9). A great variability was observed among the antimicrobial 
drugs used for the management of PRBSIs (see table 3): median 3, ranging from 1 to 7. 
ALT therapy. Vancomycin locks were used in 21/23 PRBSI (91%). The remaining 2 locks consisted 
in ciprofloxacin (n=1) that was used to treat successfully a PRBSI due to E. cloacae and in 
vancomycin plus ciprofloxacin (n=1) that was used to treat a polymocrobial PRBSI due to S. 
epidermidis and E. coli. Concerning this last patient, he died 7 days after the initiation of ALT, 
while no criteria for PRBSI treatment failure were found. A great variability of the lock duration 
was observed, ranging from 8 to 41 days. The exact duration time was lacking for 6/23 locks (26%) 
and the exact indwelling time of the lock solution within the catheter was not available. The lock 
solution was exchanged daily as long as the patient was hospitalized and weekly as soon as the 
patient was discharged (outpatient management). 10/23 locks (43%) lasted 2 weeks or more 
(range 14 – 41 days) and only 1 failure occurred (22 days of ALT). 7/23 locks (30%) lasted less than 
2 weeks (range 8 – 12). Among those seven locks, 2 (29%, 8 and 12 days) were stopped because of 
early treatment failure, 4 were successful (57%, range: 8 – 12 days), and 1 was lost to follow-up. 
Outcome. On day 180 (6 months), treatment was successful in 12/23 PRBSI and none of the 
patients had had their port removed for another reason than infection. Three patients died within 
the evaluation period without any criteria for treatment failure: the PRBSI was not the cause of 
death (all patients died because of cancer progression). 4 patients were lost to follow-up because 
they were transferred to another centre. Those 7 patients were considered as dropouts for the 
time-event analysis. Failure occurred in 4/23 of the PRBSI treated with ST and ALT: 2 early failures 
and 2 late failures (see table 3). Regarding early failures, patient 14 presented a new PRBSI on day 
12 after the initial PRBSI diagnosis. Although both PRBSIs were due to S. epidermidis, their 
antimicrobial susceptibility testing profiles were different which suggested a new infection rather 
than a relapse. The patient had been under a vancomycin lock for 8 days at the time failure 
occurred. The port was removed on day 12. Patient 19 presented a relapse on day 12 after PRBSI 
diagnosis and had already been receiving a vancomycin lock for 12 days. The port was removed 
on the same day. Regarding late failures, patient 2 and 15 presented a relapse on day 40 and 46, 
respectively. Their ports were removed 3 days after relapse diagnosis. Only one patient who 
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presented treatment failure was neutropenic at the time of diagnosis and in none of the failures 
severe PRBSI-associated complications occurred. A Kaplan-Meier analysis was performed in order 
to determine the cumulative 6-month success rate. When all the 23 episodes were analysed, a 
cumulative 6-month success rate of 78% (95% CI, 59 – 97%) was observed. Analysing only the 
PRBSI episodes that could be evaluated until the end of the 6-month study period (n=16), the 
cumulative success rate was 75% (95% CI, 53 – 96%). Figure 2 shows the cumulative success rate 
for episodes that could be evaluated until the end of the study period. Of note, patient 8 
presented a late relapse on day 205 after PRBSI diagnosis. 
Discussion 
This study confirms the data reported in the literature on PRBSI management with ST and ALT, 
with an estimated 6-month cumulative success rate of around 75%. Although the number of 
patients was low, many of the above mentioned studies had similar samples sizes, ranging from 
14 to 44 PRBSI (11–17). These data suggest that actual conservative management of selected 
cases of PRBSI in our centre is effective. Another point of interest is the fact that follow-up in this 
study was conducted over a period of 6 months (180 days)  after PRBSI diagnosis showing that 
management with ALT can be beneficial in a long-term perspective. Many of the studies that 
yielded success rates higher than 80% assessed outcome 30 days after the end of the treatment 
(13,15,17) and 2 studies with longer follow-up periods of 180 and 90 days showed lower success 
rates of 77% (16) and 18% (11), respectively. This last result was observed in onco-haematological 
children: 6/17 of them were neutropenic. Although a comparison between this paediatric 
population and that analysed in the present study cannot be made, neutropenia don’t seem to 
have played a role in our study showing a 75% success rate despite 75% of patients being 
neutropenic at time of PRBSI diagnosis.  
As far as PRBSI diagnosis is concerned, there is still some discussion about the most appropriate 
diagnostic criteria. Although clinical signs of bloodstream infection are constantly used in the 
literature, the best method to diagnose PRBSIs remains controversial. A meta-analysis of 51 
studies on the best methods for diagnosing intravascular device-related bloodstream infection 
conducted by Safdar et al came to the conclusion that “for long-term catheters (including ports) 
paired quantitative blood cultures are the most accurate test for diagnosing intravascular device-
related bloodstream infection without device removal” (18). They also mention that “clinical 
findings are unreliable because of their poor sensitivity and specificity”. For the present study, any 
positive blood culture drawn from the port or peripheral venipuncture and growing a pathogen 
consistent with PRBSI (i.e. Gram positive skin colonizer) combined with consistent clinical 
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manifestations of infection and the absence of an alternative source of infection were used for 
defining PRBSI. Some of the studied PRBSIs might thus have represented a port colonisation or 
blood culture contamination. However, as the studied population was at high risk for infections 
(neutropenic patients undergoing chemotherapy), the lower diagnostic threshold for PRBSI used 
by the physicians in charge was an acceptable pragmatic approach. 
Rijnders et al published in 2004 the first randomized, placebo-controlled trial on ALT for catheter 
related bacteraemia with catheter salvage on day 180 in 77% for the ST and ALT arm (n=23) 
versus only 43% for the ST and placebo arm (n=16) (16). Interestingly, the 2 Kaplan-Meier time to 
treatment failure analysis curves overlap during the first weeks, with most failures in the placebo 
arm occurring after 2 months. This observation does suggest the efficacy of the management 
applied in the present study, starting with ST followed by ALT. However, the timing of start ALT 
and the dwell time needed for “sterilizing” the port remain matter of controversy. Although data 
on dwell time of ALT were not available for the present study, median duration of ALT was 14 
days and in the majority of cases ALT was performed on a weekly outpatient basis. Given the 
observed success rate, this seems to support vancomycin activity during at least 2 weeks in port 
lumens (19). Another interesting finding is that patients who received only one week of ALT had 
favourable outcomes, suggesting that shorter ALT durations may be effective. One study tested 
the efficacy of a 3-day ALT and reported a success rate of 85.7% (12). 
The main limitations of this observational study are the selection bias due to the retrospective 
design and the low number of eligible patients. Only patients whose discharge report mentioned 
ST and ALT were selected. As ST always preceded ALT in the present approach, patients in whom 
port salvage with ALT following ST might have been the initial “intention-to-treat” option but who 
failed to respond to ST and required early port removal were not identified. This might have led to 
an overestimation of the success rate. Possible port blood cultures contaminations treated as 
PRBSI in 2 cases might have been another source of overestimation of the success rate, which 
illustrates the difficulty of diagnosis and management of PRBSI in clinical practice. The definition 
of PRBSI used by the physicians in charge for applying the ALT was less strict than in previous 
studies and in the current guidelines, but does reflect the real-life approach. Concerning the 
patients lost to follow-up, they were all managed by external centres/physicians and outcome 
data were not available.  
In conclusion, ST followed by ALT without port removal is an effective approach for management 
of PRBSI due to Gram positive skin microorganisms in onco-haematological patients. Although 
prospective double-blind randomized trials are needed to prove these results, there has been a 
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growing evidence in the last few years that the conservative management of PRBSI is an efficient 
option for of pathogens of low virulence. If port removal remains the recommended standard for 
more virulent pathogens such as S. aureus, Candida spp., P. aeruginosa and other Gram negatives, 
the development of new lock solutions such as ethanol or taurolidine may offer new effective 
options (20). 
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Figure 1. Algorithm of patients selection according to systematic screening of the discharge reports 
of the Isolation Ward of the Infectious Diseases Service at the Department of Medicine (CHUV), 
between January 1, 2005 and December 31, 2010. 
  
61 PRBSI 
26 PRBSI treated 
combining ST and ALT 
1 PRBSI did not meet 
inclusion criteria 
2 PRBSI with no 
available information 
23 PRBSI included in 
the study 
35 PRBSI treated 
otherwise  than 
combining ST and ALT 
28 PRBSI treated with 
ST and port removal 
2 PRBSI treated with 
systemic antifungal 
therapy and port 
removal 
4 PRBSI trated with  
ST alone 
1 PRBSI treated by  
ALT alone 
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Table 1. Microbiological data of the 61 episodes of PRBSI that occurred in the Isolation Ward of the 
Infectious Disease Service at the Department of Medicine (CHUV) over a 6-year period.  
 
Number of miccroorganisms involved 66
Polymicrobial infection 5
Gram-positive bacteria 71%
S. epidermidis 62%
S. aureus 7%
E. gallinarum 3%
S. mitis 2%
S. haemolyticus 2%
Gram-negative bacteria 17%
E. coli 10%
E. cloacae 3%
K. pneumoniae 2%
C. koseri 2%
Stenotrophomonas maltophila 2%
Other 11%
C. albicans 3%
S. agalactiae 2%
C. parapsilosis 2%
unknown 5%
sterile cultures 2%
Microorganism repartition according to PRBSI management type (%)
ST and ALT (n=26)
Gram-positive bacteria 89%
S. epidermidis 79%
E. gallinarum 7%
S. mitis 4%
Gram-negative bacteria 7%
E. cloacae 4%
E. coli 4%
unknown 4%
ST and port removal (n=28)
Gram-positive bacteria 63%
S. epidermidis 43%
S. aureus 13%
S.agalactiae 3%
S. haemolyticus 3%
Gram-negative bacteria 27%
E.coli 17%
S. maltophila 3%
C. Koseri 3%
K. pneumoniae 3%
unknown 7%
Other (ST alone, AFT and port removal, ALT alone) (n=7)
Gram-positive bacteria 50%
S. epidermidis 50%
Yeasts 38%
C. albicans 25%
C. parapsilosis 13%
sterile culture 13%
ST= Systemic antimicrobia l  Therapy; AFT= systemic AntiFungal  Therapy; ALT= 
Antibiotic Lock Therapy.
Overall microorganism repartition(%)
General microbiological caracteritics of the 61 PRBSI
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Table 2. Demographic and clinical characteristics of the 22 patients included in the study with 23 
episodes of PRBSI. 
 
 
  
22
60 (23 - 78)
Male (%) 68%
Female (%) 32%
Hematological malignancies 22/22
Acute myeloid leukemia 6/22
Myelodyspasic syndrome 1/22
Multiple myeloma 6/22
Non-Hodgkin lymphoma 6/22
Hodgking lymphoma 3/22
Solid tumor 1/22
23
Consolidation AL 1/23
Autologous-HSCT 8/23
Allogenic-HSCT 2/23
Other 10/23
None 2/23
74%
Median Duration (days) 7
Range (days) 2 - 79
Subclavian right 39%
Subclavian left 43%
Other 4%
Unknown 13%
Median  (days) 164
Range (days) 3 - 1104
Systemic manifestations
Fever 91%
Median duration (days) 3
Range (days) 1 - 13
Chills 30%
Sepsis 30%
Local signs of infection
Redness 17%
Calor 4%
Oedema 13%
Pain 22%
Purulent discharge 0%
Type of chemotherapy
Episodes of hospitalization
Port location (%)
Time elapsed from port placement to PRBSI diagnosis (n=15)
Neutropenia (%)
Clinical Presentation
Patients
Age (median) (range)
Gender
Underlying disease
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Table 2 (continued) 
 
Length of bacteremia (days) (n=21)
(median) (range) 1 (1 - 6)
Blood cultures
PAC blood cultures
Positive PAC blood cultures/total episodes of PRBSI (%) 23/23 100%
Total No of positive bottles/total No of bottles (%) 88/111 79%
Peripheral blood cultures
Positive peripheral blood cultures/total episodes of PRBSI (%) 8/23 34%
Total No of positive bottles/total No of bottles (%) 28/83 34%
Total No of positive blood culture bottles (PAC + peripheral) /total No of bottles 116/194 60%
PRBSI diagnosis
Median time elapsed from blood sample to PRBSI diagnosis (days) (range) 1 (1 - 4)
Median time elapsed from blood sample to appropriate antimicrobial treatment (days)(range) 0 (-1 - 3)
Gram-positive organisms 
S. epidermidis 21/23
S. mitis 1/23
E. gallinarum 1/23
Gram-negative organisms
E. cloacae 1/23
E. coli 1/23
Polymicrobial infections
S. epidermidis / S. mitis 1/23
S. epidermidis / E.coli 1/23
Appropriate ST  duration in days (median) (range) 14 (7 - 35)
ALT  duration in days (n=16) (median) (range) 15 (8 - 41)
Median time elapsed from PRBSI diagnosis to appropriate antimicrobial treatment (days)(range) -1 (-3 -1)
Median time elapsed from PRBSI diagnosis to ALT (days)(range) 6 (-1 - 21)
Outcome
Success 12/23
Failure 4/23
Immediate 0/23
Early 2/23
Late 2/23
Patients dead within evaluation period without known failure criteria 3/23
Patients lost to follow-up 4/23
AL= Acute Leukemia; HSCT= Hematopoietic Stem Cel l  Transplantation; ST= Systemic Therapy; ALT= Antibiotic Lock Therapy.
Antimicrobial treatment
Bacteremia characteristics according to the number of episodes of PRBSI
Microorganisms
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Table 3. Individual microbiological, treatment and outcome characteristics of the 23 episodes of PRBSI included in the study. 
 
 
 
Empirical Route
Lengtha 
(days)
Pathogen 
susceptible
Adjusted Route
Lentgth 
(days)
 Total 
(days)
Vancomycin use
vancomycin 
therapy 
duration 
(days)
Number of 
RTBC
RTBC 
(median)
RTBC (range) Drug Length (days)
1 23 M S.epidermidis HA + + vancomycin i.v. S.D. 14 yes 14 3 14.10 4.30 - 17.10 vancomycin 14 success
vancomycin i.v. S.D.
2 56 M S.epidermidis HA + + co-amoxicilline i.v. 1 yes co-amoxicilline i.v. 9 14 yes 1 0 none vancomycin unknown late failure
vancomycin i.v. 2 yes co-amoxicilline p.o. 5
3 60 M S.epidermidis HA + + cefepime i.v. 1 yes cefepime i.v. 6 14 yes 14 3 20.75 13.00 - 32.00 vancomycin 15 lost to follow-up
vancomycin i.v. 14
4 30 M S.epidermidis HA + - cefepime i.v. 3 yes vancomycin i.v. 4 35 yes 4 2 9.65 4.50 - 14.80 vancomycin unknown lost to follow-up
cefepime i.v. 3
teicoplanin i.v. 12
clindamycin p.o. 16
rifampicine p.o. 17
5 54 F S.epidermidis HA + - cefepime i.v. 5 no meropenem i.v. 10 11 yes 4 1 27.90 vancomycin 8 success
vancomycin i.v. 4 yes cubicine i.v. 11
levofloxacin p.o. 3
6 47 F S.epidermidis HA + - vancomycin i.v. 16 yes pip/tazo i.v. 1 8 yes 4 2 13.80 11.70 - 15.90 vancomycin 8 success
pip/tazo i.v. 12 no daptomycine i.v. 7
daptomycine i.v. 9 yes ciprofloxacine p.o. 6
7 65 F S.epidermidis CA + - imipenem i.v. 4 yes vancomycin i.v. 7 7 yes 7 0 none vancomycin 16 1
8 32 M S.epidermidis CA + + imipenem i.v. 3 no teicoplanin i.v. 14 14 no vancomycin unknown success
9 31 M S.epidermidis HA + nonelevofloxacinacine p.o. 2 no vancomycin i.v. 4 15 yes 4 2 24.75 19.80 - 29.70 vancomycin unknown success
teicoplanin i.v. 12
10 68 M S.epidermidis HA + - co-amoxicilline i.v. 13 13 no vancomycin 29 success
11 66 F Enterobacter cloacae HA + none imip/cilas i.v. 2 yes cefepime i.v. 3 15 no ciprofloxacine 12 success
imip/cilas i.v. 9
ciprofloxacine p.o. 4
12 78 M S.epidermidis CA + + vancomycin i.v. 4 21 yes 4 1 20.80 vancomycin unknown lost to follow-up
levofloxacin i.v. 10
levofloxacin p.o. 7
13 59 M S.epidermidis HA + + imip/cilas i.v. 2 yes imip/cilas i.v. 5 24 yes 1 (single dose) 3 30.20 29.40 - 36.40 vancomycin 37 success
vancomycin i.v. 6
flucloxacilline i.v. 1
cefepime i.v. 3
ceftriaxone i.v. 2
linezolide p.o. 10
rifampicine p.o. 10
OutcomePVC
ALTST
Patient Age Gender Microorganism PBC
Type of 
infection
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Table 3 (continued) 
14 26 M S.epidermidis HA + + cefepime i.v. 3 yes cefepime i.v. 6 14 yes 4 2 14.25 8.80 - 19.70 vancomycin 8 early failure
vancomycin i.v. 2 yes vancomycin i.v. 2
levofloxacin p.o. 5
15 64 M S.epidermidis HA + - cefepime i.v. 2 yes cefepime i.v. 3 10 yes 8 2 9.95 9.40 - 10.50 vancomycin 22 late failure
vancomycin i.v. 10
16 64 F Enterococcus gallinarum HA + - vancomycin i.v. 2 yes vancomycin i.v. 14 14 yes 16 0 none vancomycin 41 success
17 29 M S.epidermidis + S.mitis HA + - cefepime i.v. 2 no cefepime i.v. 2 8 yes 5 2 8.25 6.60 - 9.90 vancomycin 9 success
vancomycin i.v. 7
imip/cilas i.v. 5
linezolide p.o. 1
18 63 M S.epidermidis HA + - vancomycin i.v. 1 yes vancomycin i.v. 18 18 yes 19 2 14.45 12.70 - 16.20 vancomycin 24 success
rifampicine p.o. 18
19 70 F S.epidermidis HA + - cefepime i.v. 3 yes cefepime i.v. 4 12 yes 4 1 13.00 vancomycin 12 early failure
vancomycin i.v. 4
ciproflox p.o. 9
rifampicine p.o. 8
20 59 M S.epidermidis HA + - cefepime i.v. 1 no vancomycin i.v. 7 7 yes 7 1 9.30 vancomycin 8 lost to follow-up
cefepime i.v. 5
21 57 M S.epidermidis HA + - cefepime i.v. 2 yes cefepime i.v. 4 20 yes 4 0 none vancomycin 15 success
imip/cilas i.v. 8
vancomycin i.v. 6
levofloxacin p.o. 8
22 60 M S.epidermidis HA + none imip/cilas i.v. 1 no imip/cilas i.v. 3 15 yes 11 7 16.30 14.60 - 35.80 vancomycin 24 1
clarythromycin i.v. 1 no clarythromycin i.v. 3
vancomycin i.v. 11
levofloxacin p.o. 11
24 76 F S. epidermidis + E.coli CA + + cefepime i.v. 2 yes cefepime i.v. 8 17 yes 17 3 18.40 13.00 - 20.80 vancomycin unknown 1
vancomycin i.v. 17 ciprofloxacine unknown
ceftriaxone i.v. 6
PBC= Port Blood Culture; PVC=Peripheral venipuncture blood culture; ST= Systemic Therapy; ALT= Antibiotic Lock Therapy; HA= hospital-acquired infection; CA= community-acquired infection; pip/tazo= piperacill in-tazobactam; imip/cilas= imipenem-cilastatine; RTBC= residual through blood concentration. 1= patient dead within the evaluation period (note that no 
criteria of treatment failure was found in these patients).
a= length from the start of the empirical systemic antimicrobial therapy to the diagnosis of PRBSI.
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Figure 2. Kaplan-Meier analysis of successful port salvage after ST and ALT during the 180-day study 
period (n=16). Dotted lines represent the 95% confidence intervals. 
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